文献速递抗栓抗凝管理治疗药物监测与药物基因组学药物不良反应与药物警戒

基于体重指数的依诺肝素剂量方案在创伤患者静脉血栓栓塞预防中的抗Xa浓度评估

Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients.
PubMed 文献 · Pharmacotherapy · 2022-02-09

结果显示62.6%患者达到目标浓度,抗Xa浓度与按估计血容量(EBV)计算的剂量相关性最强(ρ=0.57),按EBV和总体重(TBW)分类的剂量是达到目标浓度的独立预测因素。

要点

  • 基于BMI的依诺肝素预防方案在创伤患者中达标率仅62.6%,有待改进。
  • 抗Xa浓度与按EBV计算的剂量相关性(ρ=0.57)优于TBW(ρ=0.46)和BMI(ρ=0.20)。
  • 按EBV和TBW分类的剂量是达到目标抗Xa浓度的独立预测因素(p<0.001)。

核心结论

  • 成人创伤患者使用基于BMI的依诺肝素预防方案时,达到目标抗Xa浓度的比例仍不理想,为62.6%。
  • 按EBV计算的依诺肝素剂量与抗Xa浓度的相关性优于按TBW和BMI计算的剂量。
  • 按EBV和TBW分类的剂量是达到目标抗Xa浓度的唯二显著预测因素(p<0.001)。

研究设计与样本

  • 主要结局为接受≥3剂依诺肝素后达到目标抗Xa浓度的患者百分比。
  • 次要结局包括抗Xa浓度与按BMI、TBW、EBV计算的依诺肝素剂量的相关性,以及临床相关出血和静脉血栓栓塞的发生率。
  • 采用多变量逻辑回归识别与达到目标抗Xa浓度相关的变量。

主要发现

  • 纳入患者以男性(69.7%)和黑人(50.5%)为主,平均年龄44.1岁。
  • 62.6%的患者达到目标抗Xa浓度。
  • 抗Xa浓度与按EBV计算的剂量呈中度相关(ρ=0.57),其次为按TBW计算的剂量(ρ=0.46),按BMI计算的剂量相关性较弱(ρ=0.20)。
  • 多变量逻辑回归显示,按EBV和按TBW分类的剂量是达到目标抗Xa浓度的唯二显著预测因素(p<0.001)。

临床怎么用

  • 在创伤患者中采用基于BMI的依诺肝素预防方案时,应关注抗Xa浓度达标情况,必要时进行监测。
  • 考虑按EBV或TBW计算依诺肝素剂量可能比按BMI计算更有利于达到目标抗Xa浓度。

局限性

  • 原文未报告临床相关出血和静脉血栓栓塞的具体发生率数据。
  • 需进一步研究以明确最佳的基于EBV和TBW的剂量方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the effectiveness of a body mass index (BMI)-based enoxaparin prophylaxis dosing protocol at achieving target anti-factor Xa (anti-Xa) concentrations in the trauma population. METHODS: This retrospective chart review evaluated anti-Xa concentrations in adult trauma patients who received prophylactic enoxaparin over a three-month period. The primary outcome was the percentage of patients that achieved target anti-Xa concentrations after ≥3 doses of enoxaparin. Secondary outcomes included correlations of anti-Xa concentrations with enoxaparin dose per BMI, total body weight (TBW), and estimated blood volume (EBV). The prevalence of clinically relevant bleeding and venous thromboembolism was also recorded. Multivariable logistic regression was used to identify associated variables for target anti-Xa concentration attainment. RESULTS: Ninety-nine consecutive patients were included in the study. Included patients were predominately male (69.7%) and Black (50.5%) with a mean age of 44.1 years. Target anti-Xa concentrations were achieved in 62.6% of patients. Anti-Xa concentrations were moderately correlated with enoxaparin dose per EBV (ρ = 0.57), followed by dose per TBW (ρ = 0.46), and dose per BMI (ρ = 0.20). Multivariable logistic regression demonstrated that categorization of enoxaparin dose per EBV and per TBW were the only statistically significant predictors of reaching target anti-Xa concentrations (p = <0.001). CONCLUSIONS: In adult trauma patients, the rate of achieving target anti-Xa concentrations remains suboptimal and provides room for further improvement. Enoxaparin dose per EBV was more closely correlated with anti-Xa concentrations when compared to TBW and BMI. Dosing per EBV and TBW was the only variables associated with reaching target anti-Xa concentrations within the study. Further investigation is warranted to elucidate optimal EBV- and TBW-based dosing regimens.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. O'Keefe MM, Carver TW, Herrmann DJ, et al. Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients. Pharmacotherapy. 2022. PMID: 35100448. doi:10.1002/phar.2665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。